Bristol-Myers Squibb Company (BMY) Release: Phase 3 Study Evaluating Yervoy® (Ipilimumab) For Melanoma In An Adjuvant Setting Meets Primary Endpoint Of Recurrence-Free Survival
6/2/2014 8:42:28 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a Phase 3 randomized, double blind study demonstrating that Yervoy (ipilimumab) 10 mg/kg (n=475) significantly improved recurrence-free survival (RFS, the length of time before recurrence or death) vs. placebo (n=476) for patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection, an adjuvant setting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by